Gilead Sciences adds 140 jobs in Ireland with new Dublin base

Gilead Sciences has operated in Ireland for 20 years with operations in Dublin and Cork.
By Ciarán Sunderland

140 new jobs have been announced at a company that has designed a drug to treat Covid-19.

Gilead Sciences is opening a new base in Dublin as part of a €7m investment.

Some of the roles will also be at the company's existing operation in Carrigtwohill in Cork.

The company has already started recruiting in areas such as clinical development, IT and HR, and expects the positions to be filled by early 2022.

Gilead Sciences expects to fill at least 80 of those new roles in the next 12 months and is currently searching for a location for its new Dublin operation.

The biopharmaceutical company already employs 370 people in Ireland and has up to date invested €225m over the past 20 years. 

The company has expanded its operations in Ireland to include drug product manufacturing and packaging for Europe and other markets outside the United States. 

Tánaiste and Minister for Enterprise, Trade & Employment Leo Varadkar welcomed the investment and praised Gilead Science's commitment to Ireland. 

Mr Varadkar said: "Gilead has been steadily growing its presence here over the last 20 years and today’s announcement underlines the company’s commitment to Ireland. 

“This expansion shows that Ireland offers the right conditions – particularly our skilled and talented workforce – to allow companies like Gilead to grow their operations here. I wish them well in this next exciting chapter.”

Gilead Sciences' operations in Ireland include a drug product manufacturing and packing facility in Carrigtwohill Co. Cork that manufactures and packages drug products. 

The facility manufactures HIV and HCV solid oral products and represents 25% of Gilead’s total solid oral drug production. 

A distribution centre in Dublin works with 90 markets worldwide while the company also has a financial shared services centre in Little Island, Co. Cork, which supports Gilead affiliates in Europe, Middle East, Asia and South America. 

Speaking about the new investment, David Cadogan, Vice President, Manufacturing Operations and General Manager, Gilead Sciences Ireland said: "Gilead has a long record of operating in Ireland and our teams here have played a critical role in ensuring that patients in Europe and other parts of the world outside of the United States have access to our medicines. 

“With this additional investment, we are looking forward to continuing this important work and growing our presence here in Ireland.”



Most Read in Business